Nelson And Nicholsan Biotech Limted Profile
Key Indicators
- Authorised Capital ₹ 2.10 M
as on 25-05-2024
- Paid Up Capital ₹ 1.54 M
as on 25-05-2024
- Company Age 18 Year, 27 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.51 M
as on 25-05-2024
- Revenue 0.24%
(FY 2017)
- Profit 5.40%
(FY 2017)
- Ebitda 3.40%
(FY 2017)
- Net Worth 18.24%
(FY 2017)
- Total Assets 9.11%
(FY 2017)
About Nelson And Nicholsan Biotech Limted
The Company is engaged in the Trading Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.10 M and a paid-up capital of Rs 1.54 M.
The company currently has active open charges totaling ₹1.51 M.
Rajani Kaushal, Anjana Kumari, Renu Gupta, and Three other members serve as directors at the Company.
- CIN/LLPIN
U24239BR2006PTC012738
- Company No.
012738
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Dec 2006
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Patna
Industry
Company Details
- Location
Patna, Bihar, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Nelson And Nicholsan Biotech Limted?
Board Members(6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajani Kaushal  | Director | 01-Apr-2013 | Current |
| Anjana Kumari | Director | 01-Jun-2020 | Current |
| Renu Gupta | Director | 01-Apr-2013 | Current |
| Neelam Sinha | Director | 08-Dec-2006 | Current |
| Sujit Gupta | Director | 08-Dec-2006 | Current |
| Sarita Kumari | Director | 01-Oct-2018 | Current |
Financial Performance of Nelson And Nicholsan Biotech Limted.
Nelson And Nicholsan Biotech Private Limted, for the financial year ended 2017, experienced modest growth in revenue, with a 0.24% increase. The company also saw a slight improvement in profitability, with a 5.4% increase in profit. The company's net worth Soared by an impressive increase of 18.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nelson And Nicholsan Biotech Limted?
In 2017, Nelson And Nicholsan Biotech Limted had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 24 Jan 2023 | ₹1.51 M | Open |
How Many Employees Work at Nelson And Nicholsan Biotech Limted?
Nelson And Nicholsan Biotech Limted has a workforce of 29 employees as of Apr 11, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nelson And Nicholsan Biotech Limted, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nelson And Nicholsan Biotech Limted's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
